Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 0.67 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.67 |
| ▸ | KIT | P10721 | 2/20 | 0.67 |
| ▸ | ABL1 | P00519 | 1/20 | 0.67 |
| ▸ | BCR | P11274 | 1/20 | 0.67 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.65 |
| ▸ | XDH | P47989 | 2/20 | 0.61 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.58 |
| ▸ | CLK1 | P49759 | 1/20 | 0.55 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.55 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31207830 | 1.00 | FLT3 (0.67) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL2815266 | 0.87 | FLT3 (0.56) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL30694751 | 0.83 | XDH (0.61) | PDGFRBXDHPDGFRAKDM4EALDH1A1 | |
| SCHEMBL31310313 | 0.83 | RAB9A (0.72) | FLT3PDGFRBXDHPDGFRAHRH4 | |
| SCHEMBL214096 | 0.83 | RAB9A (0.72) | FLT3PDGFRBXDHPDGFRAHRH4 | |
| SCHEMBL829213 | 0.83 | KDM4E (0.76) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL617200 | 0.82 | XDH (0.59) | FLT3PDGFRBXDHPDGFRAHRH4 | |
| SCHEMBL3963537 | 0.82 | F7 (0.66) | FLT3PDGFRBXDHHRH4RAB9A | |
| SCHEMBL217291 | 0.82 | XDH (0.63) | FLT3PDGFRBKITABL1BCR | |
| SCHEMBL1104006 | 0.82 | PDGFRB (0.77) | FLT3PDGFRBXDHPDGFRAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-26 | — | — | US | disclosed |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CAMBRIDGE ENTPR LTD (GB) | 2026-03-12 | — | — | US | disclosed |
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | WMT AG (DE) | 2026-01-29 | — | — | US | disclosed |
| EP-4313156-B1 | DISULFIDE-BASED PRODRUG COMPOUNDS | UNIV MUENCHEN LUDWIG MAXIMILIANS (DE) | 2025-08-06 | — | — | EP | disclosed |
| EP-4584249-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584267-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| EP-4584265-A1 | NOVEL COMPOUNDS, COMPOSITIONS AND THERAPEUTIC USES THEREOF | Cambridge Enterprise Limited (GB) | 2025-07-16 | — | — | EP | disclosed |
| CN-118974040-A | N- (3- (benzo [ B ] thiophen-2-amido) -phenyl) -2, 3-dihydrobenzo [ B ] [1,4] dioxin-6-amide derivatives and related compounds as lactic acid/ATP production inhibitors for the treatment of cancer | 威马特股份公司 | 2024-11-15 | — | — | CN | disclosed |
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-06-27 | — | — | US | disclosed |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | LUDWIG-MAXIMILIANS-UNIVERSITAT MUNCHEN (DE) | 2024-05-16 | — | — | US | disclosed |
| WO-2000042213-A1 | A NOVEL METHOD FOR DESIGNING PROTEIN KINASE INHIBITORS | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 2000-07-20 | — | — | WO | disclosed |
| EP-0664792-B1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO INC (US) | 2000-01-05 | — | — | EP | disclosed |
| EP-0863893-A1 | FIBRINOGEN RECEPTOR ANTAGONIST | Merck & Co., Inc. (US) | 1998-09-16 | — | — | EP | disclosed |
| US-5789421-A | PIPERIDINYL(METHOXY)-2-INDOLECARBONYL-2-PHENYLSULFONYLAMINO BETA-ALANINE AND SALTS FOR INHIBITING AGGREGATION OF BLOOD PLATELETS AS ANTICOAGULANTS | MERCK & CO., INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-5721253-A | Fibrinogen receptor antagonists | MERCK & CO., INC. (US) | 1998-02-24 | — | — | US | disclosed |
| WO-1997015568-A1 | FIBRINOGEN RECEPTOR ANTAGONIST | MERCK & CO., INC. (US) | 1997-05-01 | — | — | WO | disclosed |
| EP-0664792-A4 | FIBRINOGEN RECEPTOR ANTAGONISTS. | MERCK & CO INC (US) | 1996-09-25 | — | — | EP | disclosed |
| US-5559127-A | ANTICOAGULANTS | MERCK & CO., INC. (US) | 1996-09-24 | — | — | US | disclosed |
| EP-0664792-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO. INC. (US) | 1995-08-02 | — | — | EP | disclosed |
| WO-1994008962-A1 | FIBRINOGEN RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 1994-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240207414-A1 | DISULFIDE-BASED PRODRUG COMPOUND | CBS, MSR1, P4HB | FLT3 2066/4885PDGFRB 3635/4885KIT 3487/4885 |
| US-20260085062-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK1G1, CSNK2A3 | FLT3 2930/4885PDGFRB 2365/4885KIT 3638/4885 |
| US-20240156965-A1 | DICHALCOGENIDE PRODRUGS | DHCR7, DECR1, CYP27A1 | FLT3 2156/4885PDGFRB 3345/4885KIT 3340/4885 |
| US-20260070901-A1 | NOVEL COMPOUNDS AS CK2 INHIBITORS | CSNK1A1, CSNK2A3, CSNK1G1 | FLT3 3030/4885PDGFRB 2069/4885KIT 3358/4885 |
| US-20260028334-A1 | N-(3-(BENZO[B]THIOPHENE-2-CARBOXAMIDO)-PHENYL)-2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS LACTATE/ATP PRODUCTION INHIBITORS FOR THE TREATMENT OF CANCER | LDHA, LDHB, SLC6A1 | FLT3 3793/4885PDGFRB 3223/4885KIT 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.